Adoptively transferred T lymphocytes engineered to express chimeric antigen receptors (CAR) targeting CD19 are curative for some patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL; refs. 1–4). The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.